U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Unknown
149124
Substance Class Protein
Created
by admin
on Wed Apr 02 20:03:26 GMT 2025
Edited
by admin
on Wed Apr 02 20:03:26 GMT 2025
Protein Type MONOCLONAL ANTIBODY CONJUGATE
Protein Sub Type IGG1|KAPPA
Sequence Origin HUMANIZED MOUSE
Sequence Type COMPLETE
Record UNII
MNX9BG4BZK
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
Caxmotabart Entudotin
Common Name English
H-gamma1 heavy chain humanized (1-450) [VH (Homo sapiens IGHV3-66*01 (81.6%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.8.13] (26-33.51-58.97-109)) (1-120) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 CH1 K120, CH3 E12, M14 (CH1 R120>K (217) (121-218), hinge 1-
Preferred Name English
immunoglobulin G1-kappa, anti-[Homo sapiens ERBB2 (receptor tyrosine-protein kinase erbB-2, epidermal growth factor receptor 2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)], humanized monoclonal antibody, conjugated on an average of two cysteinyl residu
Common Name English
caxmotabart entudotin [INN]
Common Name English
Immunoglobulin G1, anti-(human epidermal growth factor receptor HER2) (human-Mus musculus monoclonal rhuMab HER2 ?1-chain), disulfide with human-Mus musculus monoclonal rhuMab HER2 ?-chain fusion protein with peptide (GGGGGGGC), dimer, 222??,222???-bis(t
Common Name English
Code System Code Type Description
CAS
2930814-97-2
Created by admin on Wed Apr 02 20:03:26 GMT 2025 , Edited by admin on Wed Apr 02 20:03:26 GMT 2025
PRIMARY
INN
13278
Created by admin on Wed Apr 02 20:03:26 GMT 2025 , Edited by admin on Wed Apr 02 20:03:26 GMT 2025
PRIMARY
SMS_ID
300000056825
Created by admin on Wed Apr 02 20:03:26 GMT 2025 , Edited by admin on Wed Apr 02 20:03:26 GMT 2025
PRIMARY
FDA UNII
MNX9BG4BZK
Created by admin on Wed Apr 02 20:03:26 GMT 2025 , Edited by admin on Wed Apr 02 20:03:26 GMT 2025
PRIMARY
NCI_THESAURUS
C172821
Created by admin on Wed Apr 02 20:03:26 GMT 2025 , Edited by admin on Wed Apr 02 20:03:26 GMT 2025
PRIMARY
From To
2_223 4_214
1_223 3_214
4_134 4_194
4_23 4_88
3_134 3_194
3_23 3_88
1_232 2_232
1_229 2_229
2_370 2_428
2_264 2_324
2_147 2_203
2_22 2_96
1_370 1_428
1_264 1_324
1_147 1_203
1_22 1_96
Glycosylation Type MAMMALIAN
Glycosylation Link Type Site
N 1_300
N 2_300
Related Record Type Details
RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2
TARGET->LIGAND
Caxmotabart
PARENT -> CONJUGATE
Related Record Type Details
Caxmotabart Entudotin
ACTIVE MOIETY

Structural Modifications

Modification Type Location Site Location Type Residue Modified Extent Fragment Name Fragment Approval
AMINO ACID REMOVAL [1_450] [2_450] C-TERMINUS K LYSINE K3Z4F929H6
Name Property Type Amount Referenced Substance Defining Parameters References
Molecular Formula CHEMICAL
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966